Company Filing History:
Years Active: 2014
Title: The Innovations of Victor E. Velculesu
Introduction
Victor E. Velculesu, based in Baltimore, MD, is an influential figure in the field of cancer research. With a significant contribution to the understanding of breast and colorectal cancers, his work emphasizes the importance of genetic mutations in tumor development. His insights have paved the way for new diagnostic and therapeutic approaches in oncology.
Latest Patents
Victor holds a patent titled "Consensus coding sequences of human breast and colorectal cancers." This groundbreaking patent emerged from the analysis of 13,023 genes across 11 breast and 11 colorectal cancer samples. The findings revealed that individual tumors accumulate an average of approximately 90 mutant genes, but only a specific subset contributes to the neoplastic process. Notably, the research identified 189 genes, with an average of 11 per tumor, that were mutated at significant frequency. Many of these genes had not been previously recognized as genetically altered in tumors and are anticipated to influence various cellular functions, including transcription, adhesion, and invasion. This data enriches the genetic landscape of breast and colorectal cancers and highlights potential targets for both diagnostic and therapeutic interventions.
Career Highlights
Victor E. Velculesu is affiliated with The Johns Hopkins University, a prestigious institution known for its contributions to medical research. His role there has enabled groundbreaking work in cancer genetics, enhancing our grasp of tumor biology and therapeutic opportunities. His focus on innovative research has established him as a leading voice in oncology.
Collaborations
Throughout his career, Victor has collaborated with notable colleagues, including Tobias Sjoblom and Sian Jones. These partnerships have amplified his research's impact, leading to valuable insights and advancements in the fight against cancer.
Conclusion
Victor E. Velculesu exemplifies the dedication and innovation required in cancer research. His patented work on gene mutations provides critical resources for future diagnostic and therapeutic strategies. With ongoing research and collaboration, his contributions continue to be pivotal in the quest to improve cancer treatment and patient outcomes.